Xenon Pharmaceuticals (XENE) Stock Plummets 25% After Psychiatric Trial Halt

Key Takeaways

• Azetukalner’s New Drug Application for focal seizures was submitted, representing Xenon’s potential debut commercial therapy
• Neuropsychiatric safety concerns forced the biotech to halt new enrollments in depression and bipolar disorder studies
• Shares collapsed 25% to $42.84 during Friday’s premarket session
• Analyst opinions diverged: Deutsche Bank downgraded to Hold at $46, while Needham maintained Buy with reduced $60 target
• Wells Fargo remained bullish, noting the safety issues don’t affect epilepsy prospects

Xenon Pharmaceuticals made waves Thursday by submitting a New Drug Application for azetukalner targeting focal seizures, potentially unlocking its inaugural marketed therapy. However, optimism evaporated rapidly.

Simultaneously, the biotechnology firm disclosed it was stopping fresh patient enrollments across its major depressive disorder and bipolar depression studies. The culprit: elevated frequencies of neuropsychiatric complications, encompassing confusion, drowsiness, coordination problems, and isolated psychosis incidents.

Xenon Pharmaceuticals Inc., XENE

The stock cratered 25% to $42.84 before regular market hours Friday. Should these declines persist through the session, it would represent the equity’s steepest single-day plunge since March 2017’s record 53% collapse. The price would also hit its lowest level in half a year.

Management emphasized the adverse reactions aligned with azetukalner’s established safety characteristics but hadn’t emerged during prior clinical investigations. Leadership characterized the enrollment suspension as presumably temporary and precautionary.

The pharmaceutical developer indicated it would assess dosing adjustments, potentially incorporating gradual titration or reduced amounts, to enhance patient tolerance before restarting enrollment activities.

Analyst Community Divides Over Implications

Deutsche Bank’s David Hoang moved XENE from Buy to Hold while dramatically reducing his valuation from $90 to $46. His rationale centered on concerns that these developments undermine azetukalner’s competitive positioning within focal epilepsy therapeutics.

Conversely, Wells Fargo analyst Benjamin Burnett maintained his Overweight stance. His assessment concluded the psychiatric program interruption carries no implications for the focal onset seizures program’s viability.

Needham reduced expectations from $78 to $60 while preserving its Buy recommendation. The research house eliminated all revenue forecasts tied to major depressive disorder and bipolar disorder applications from its azetukalner financial projections.

Needham highlighted ambiguity surrounding whether dosage refinements can mitigate neuropsychiatric complications without compromising therapeutic efficacy to clinically meaningful levels.

Clinical Development Status and Future Direction

Before the suspension, the X-NOVA2 phase 3 investigation for major depressive disorder had recruited 80% of its planned 450-participant cohort. Top-line data remains anticipated during 2027’s first quarter.

Company officials stated that decisions regarding resumption of depression and bipolar disorder investigations will follow X-NOVA2 data release.

H.C. Wainwright preserved its Buy rating alongside a $74 valuation, emphasizing the absence of FDA apprehensions regarding insufficient drug exposure during pre-NDA consultations for the epilepsy submission.

Xenon maintains a net cash position on its balance sheet. InvestingPro’s valuation framework calculated the equity’s fair value at $52.77, indicating shares traded above fundamental value even preceding Friday’s downturn.

Wall Street consensus doesn’t anticipate profitability for Xenon during the current year. Prior to Thursday’s announcement, the stock had appreciated 52% across the trailing twelve-month period.

Needham’s adjusted $60 target exclusively incorporates azetukalner’s epilepsy opportunity, completely eliminating psychiatric indication contributions from valuation calculations.